Aptevo Therapeutics Inc. (FWB:AP82) Financings

Aptevo Therapeutics Inc.

Financings

RaiseDate
Warrant exercise of common stock on exercise of existing warrants
Closed: US$3M raised · US$1.08 a share · Warrants at US$1.08 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners
Use of proceeds: Working capital purposes
Nov 12, 2026
Common stock on exercise of existing warrants
Closed: US$4.03 a share · Warrants at US$4.03 for 60 months · Roth Capital Partners, LLC
Dealers: Roth Capital Partners, LLC (lead)
Use of proceeds: Working capital
Aug 13, 2026
Private placement of unregistered shares of common stock (or pre-funded warrants) with common warrants
Closed: US$4.03 a share · Warrants at US$4.03 for 60 months · Roth Capital Partners, LLC
Dealers: Roth Capital Partners, LLC (lead)
Use of proceeds: Working capital
Aug 13, 2026
Shares under equity line of credit
Announced: raise
Buyers: Yorkville Advisors Global, LP (counterparty to $60 million equity line of credit; Aptevo may sell shares to it from time to time)
Use of proceeds: Support ongoing clinical development, advance preclinical programs and fund general corporate purposes
Jan 9, 2026
Registered direct offering of common stock or pre-funded warrants and common warrants
Closed: US$8M raised · US$3.25 a share · Warrants at US$3.25 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners (lead)
Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes
Jun 20, 2025
Registered direct offering of common stock
Closed: US$2M raised · US$0.862 a share · Roth Capital Partners
Dealers: Roth Capital Partners (lead)
Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes
Apr 22, 2025
Registered direct offering of common stock and warrants in concurrent private placement
Closed: US$2.1M raised · US$1.19 a share · Warrants at US$1.19 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners (lead)
Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes
Apr 4, 2025
Warrant exercise of common stock upon exercise of existing warrants
Announced: about US$6.2M · US$7.5 a share · Warrants at US$9.53 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners
Use of proceeds: Working capital and general corporate purposes
Dec 12, 2024

Read by 6ix AI from the company's releases